{"id":457356,"date":"2021-03-15T07:33:09","date_gmt":"2021-03-15T11:33:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=457356"},"modified":"2021-03-15T07:33:09","modified_gmt":"2021-03-15T11:33:09","slug":"corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/","title":{"rendered":"Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda\u00ae) in Patients with Adrenal Cancer with Cortisol Excess"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MENLO PARK, Calif., March  15, 2021  (GLOBE NEWSWIRE) &#8212; Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of the first patient in the Phase 1b trial of relacorilant in combination with the PD-1 checkpoint inhibitor pembrolizumab (Merck\u2019s medication, Keytruda<sup>\u00ae<\/sup>) in patients with adrenal cancer with cortisol excess.<\/p>\n<p align=\"justify\">\u201cCortisol activity blunts the cancer-killing attributes of immunotherapeutic agents such as checkpoint inhibitors,\u201d said Andreas Grauer, MD, Corcept\u2019s Chief Medical Officer, \u201cwhich may be why pembrolizumab is rarely effective as monotherapy in patients with adrenal cancer with cortisol excess. Our trial will examine whether adding relacorilant to pembrolizumab therapy will reduce cortisol-activated immune suppression sufficiently to help pembrolizumab achieve its intended tumor-killing effect, while relacorilant treats the Cushing\u2019s syndrome caused by excess cortisol activity.\u201d<\/p>\n<p align=\"justify\">The open-label, Phase 1b trial has a planned enrollment of 20 patients with metastatic or unresectable adrenal cancer with cortisol excess at five sites in the United States.<\/p>\n<p>\n        <strong>About Relacorilant<\/strong>\n      <\/p>\n<p align=\"justify\">Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor that does not bind to the body&#8217;s other hormone receptors. Corcept is studying relacorilant in a variety of serious disorders, including Cushing\u2019s syndrome and adrenal, ovarian and pancreatic cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents. Relacorilant has received orphan drug designation in the United States for the treatment of Cushing\u2019s syndrome and pancreatic cancer.<\/p>\n<p>\n        <strong>About Corcept Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym<sup>\u00ae<\/sup> was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing\u2019s syndrome. Corcept has discovered a large portfolio of proprietary compounds, including relacorilant, that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially from those statements express or imply. These risks and uncertainties include, but are not limited to, the progress, enrollment, timing, design and results of our clinical trials; our ability to operate our business and achieve our goals and conduct our clinical trials during the COVID-19 pandemic;\u00a0the availability of competing treatments; risks related to the development of relacorilant as a product candidate for adrenal cancer with cortisol excess, including its clinical attributes, regulatory approvals, mandates and oversight, and other requirements; and the scope and protective power of our intellectual property. In this press release, forward-looking statements include those concerning the clinical attributes of relacorilant and its effects in patients with adrenal cancer. These and other risks are set forth in our\u00a0SEC\u00a0filings, which are available at our website and the SEC\u2019s website. We disclaim any intention or duty to update forward-looking statements made in this press release.<\/p>\n<p align=\"justify\">\n        <em>Keytruda<\/em><br \/>\n        <sup><br \/>\n          <em>\u00ae<\/em><br \/>\n        <\/sup><br \/>\n        <em> is a registered trademark of Merck &amp; Co, Inc.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>Christopher S. James, MD<br \/>Director, Investor Relations<br \/>Corcept Therapeutics<br \/>650-684-8725<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nsSSKWMl5yfO_kOdJIWYu1g-OOyPkYDT0glnXozlnU0Zlkpywn0Fb6-6Oa-XIF2JcGSP6Jqsn-zEN7ybzvwojj9MUzToR28iN1Kwd8lrNo4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">cjames@corcept.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zghUr0k3Wl7EhS_dzhJH4hEBBDMLMbFJgntDbeU9kltL7qXQEvVx3I0JFoZHvajkFMB5--mwis-1rvxtbmGylA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.corcept.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTY4OSM0MDYyNTk3IzIwOTAwODY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/f9574fe1-d4ec-494c-8175-2f30af14e6aa\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MENLO PARK, Calif., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of the first patient in the Phase 1b trial of relacorilant in combination with the PD-1 checkpoint inhibitor pembrolizumab (Merck\u2019s medication, Keytruda\u00ae) in patients with adrenal cancer with cortisol excess. \u201cCortisol activity blunts the cancer-killing attributes of immunotherapeutic agents such as checkpoint inhibitors,\u201d said Andreas Grauer, MD, Corcept\u2019s Chief Medical Officer, \u201cwhich may be why pembrolizumab is rarely effective as monotherapy in patients with adrenal cancer with cortisol excess. Our trial will examine whether adding relacorilant to pembrolizumab &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda\u00ae) in Patients with Adrenal Cancer with Cortisol Excess&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-457356","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda\u00ae) in Patients with Adrenal Cancer with Cortisol Excess - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda\u00ae) in Patients with Adrenal Cancer with Cortisol Excess - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MENLO PARK, Calif., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of the first patient in the Phase 1b trial of relacorilant in combination with the PD-1 checkpoint inhibitor pembrolizumab (Merck\u2019s medication, Keytruda\u00ae) in patients with adrenal cancer with cortisol excess. \u201cCortisol activity blunts the cancer-killing attributes of immunotherapeutic agents such as checkpoint inhibitors,\u201d said Andreas Grauer, MD, Corcept\u2019s Chief Medical Officer, \u201cwhich may be why pembrolizumab is rarely effective as monotherapy in patients with adrenal cancer with cortisol excess. Our trial will examine whether adding relacorilant to pembrolizumab &hellip; Continue reading &quot;Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda\u00ae) in Patients with Adrenal Cancer with Cortisol Excess&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-15T11:33:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTY4OSM0MDYyNTk3IzIwOTAwODY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda\u00ae) in Patients with Adrenal Cancer with Cortisol Excess\",\"datePublished\":\"2021-03-15T11:33:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\\\/\"},\"wordCount\":589,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTY4OSM0MDYyNTk3IzIwOTAwODY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\\\/\",\"name\":\"Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda\u00ae) in Patients with Adrenal Cancer with Cortisol Excess - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTY4OSM0MDYyNTk3IzIwOTAwODY=\",\"datePublished\":\"2021-03-15T11:33:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTY4OSM0MDYyNTk3IzIwOTAwODY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTY4OSM0MDYyNTk3IzIwOTAwODY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda\u00ae) in Patients with Adrenal Cancer with Cortisol Excess\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda\u00ae) in Patients with Adrenal Cancer with Cortisol Excess - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/","og_locale":"en_US","og_type":"article","og_title":"Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda\u00ae) in Patients with Adrenal Cancer with Cortisol Excess - Market Newsdesk","og_description":"MENLO PARK, Calif., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of the first patient in the Phase 1b trial of relacorilant in combination with the PD-1 checkpoint inhibitor pembrolizumab (Merck\u2019s medication, Keytruda\u00ae) in patients with adrenal cancer with cortisol excess. \u201cCortisol activity blunts the cancer-killing attributes of immunotherapeutic agents such as checkpoint inhibitors,\u201d said Andreas Grauer, MD, Corcept\u2019s Chief Medical Officer, \u201cwhich may be why pembrolizumab is rarely effective as monotherapy in patients with adrenal cancer with cortisol excess. Our trial will examine whether adding relacorilant to pembrolizumab &hellip; Continue reading \"Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda\u00ae) in Patients with Adrenal Cancer with Cortisol Excess\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-15T11:33:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTY4OSM0MDYyNTk3IzIwOTAwODY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda\u00ae) in Patients with Adrenal Cancer with Cortisol Excess","datePublished":"2021-03-15T11:33:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/"},"wordCount":589,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTY4OSM0MDYyNTk3IzIwOTAwODY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/","name":"Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda\u00ae) in Patients with Adrenal Cancer with Cortisol Excess - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTY4OSM0MDYyNTk3IzIwOTAwODY=","datePublished":"2021-03-15T11:33:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTY4OSM0MDYyNTk3IzIwOTAwODY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTY4OSM0MDYyNTk3IzIwOTAwODY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda-in-patients-with-adrenal-cancer-with-cortisol-excess\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda\u00ae) in Patients with Adrenal Cancer with Cortisol Excess"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=457356"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457356\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=457356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=457356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=457356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}